The United Kingdom and the United States have announced a major bilateral deal that will preserve zero levies on UK drug products going into the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to raise spending on medicines through the National Health Service (NHS). This pledge ensures that duties on these vital exports will be held at nothing for a timeframe of the next three years.
This development comes after earlier statements to hike import taxes on branded pharmaceutical imports, with figures floated as high as one hundred percent.
"This agreement between the Britain strengthens the global environment for innovative medicines and introduces long-overdue balance to American-British pharmaceutical trade," a statement declared.
Commercial Impact
Pharmaceuticals constitute one of the Britain's largest export categories to the United States, which is easily the largest market for leading companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months to the end of September, the UK exported drugs worth over eleven billion pounds to the US. This amount accounted for a significant portion of British export trade in that period.
"This deal safeguards work, stimulates funding and facilitates the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Detailed British Pledges
The agreement includes several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to raise overall public funding on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to prevent overspending will be restricted at fifteen percent. Previously, repayments exceeded twenty percent.
Industry Background
This agreement follows a protracted row between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
The disagreement were intensified by assertions that American customers were charged significantly more for the identical medicines than people in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had declined as a share of its resources over the previous ten-year period.
